These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 32760425)

  • 21. Modulation of aberrant splicing in human RNA diseases by chemical compounds.
    Kataoka N
    Hum Genet; 2017 Sep; 136(9):1237-1245. PubMed ID: 28364159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global Gene Expression Profiling and Alternative Splicing Events during the Chondrogenic Differentiation of Human Cartilage Endplate-Derived Stem Cells.
    Shang J; Fan X; Shangguan L; Liu H; Zhou Y
    Biomed Res Int; 2015; 2015():604972. PubMed ID: 26649308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RNA interference: a potential therapeutic tool for silencing splice isoforms linked to human diseases.
    Gaur RK
    Biotechniques; 2006 Apr; Suppl():15-22. PubMed ID: 16629383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNA structure in alternative splicing regulation: from mechanism to therapy.
    Bao N; Wang Z; Fu J; Dong H; Jin Y
    Acta Biochim Biophys Sin (Shanghai); 2024 Jul; ():. PubMed ID: 39034824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long Non-Coding RNA Expression Levels Modulate Cell-Type-Specific Splicing Patterns by Altering Their Interaction Landscape with RNA-Binding Proteins.
    Porto FW; Daulatabad SV; Janga SC
    Genes (Basel); 2019 Aug; 10(8):. PubMed ID: 31390792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapeutic approach to primary and metastatic brain tumors: I. CD44 variant pre-RNA alternative splicing as a CEPT control element.
    Asman DC; Dirks JF; Ge L; Resnick NM; Salvucci LA; Gau JT; Becich MJ; Cooper DL; Dougherty GJ
    J Neurooncol; 1995 Dec; 26(3):243-50. PubMed ID: 8750190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alternative splicing and its role in pathologies of the endocrine system.
    Piekiełko-Witkowska A; Nauman A
    Endokrynol Pol; 2011; 62(2):160-70. PubMed ID: 21528479
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Splicing and cancer: Challenges and opportunities.
    Coltri PP; Dos Santos MGP; da Silva GHG
    Wiley Interdiscip Rev RNA; 2019 May; 10(3):e1527. PubMed ID: 30773852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sequence and Evolutionary Features for the Alternatively Spliced Exons of Eukaryotic Genes.
    Chen SY; Li C; Jia X; Lai SJ
    Int J Mol Sci; 2019 Aug; 20(15):. PubMed ID: 31390737
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transcriptome-wide analysis of alternative mRNA splicing signature in the diagnosis and prognosis of stomach adenocarcinoma.
    Shi Y; Chen Z; Gao J; Wu S; Gao H; Feng G
    Oncol Rep; 2018 Oct; 40(4):2014-2022. PubMed ID: 30106437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Splicing in the Treatment of Human Disease.
    Suñé-Pou M; Prieto-Sánchez S; Boyero-Corral S; Moreno-Castro C; El Yousfi Y; Suñé-Negre JM; Hernández-Munain C; Suñé C
    Genes (Basel); 2017 Feb; 8(3):. PubMed ID: 28245575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptidic tools applied to redirect alternative splicing events.
    Nancy MM; Nora RM; Rebeca MC
    Peptides; 2015 May; 67():1-11. PubMed ID: 25748022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and In Vitro Use of Antisense Oligonucleotides to Correct Pre-mRNA Splicing Defects in Inherited Retinal Dystrophies.
    Garanto A; Collin RWJ
    Methods Mol Biol; 2018; 1715():61-78. PubMed ID: 29188506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms and Regulation of Alternative Pre-mRNA Splicing.
    Lee Y; Rio DC
    Annu Rev Biochem; 2015; 84():291-323. PubMed ID: 25784052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Splicing modulation mediated by small nuclear RNAs as therapeutic approaches for muscular dystrophies.
    Benchaouir R; Goyenvalle A
    Curr Gene Ther; 2012 Jun; 12(3):179-91. PubMed ID: 22515846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normal and altered pre-mRNA processing in the DMD gene.
    Tuffery-Giraud S; Miro J; Koenig M; Claustres M
    Hum Genet; 2017 Sep; 136(9):1155-1172. PubMed ID: 28597072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Splicing dysregulation in cancer: from mechanistic understanding to a new class of therapeutic targets.
    Wang Y; Bao Y; Zhang S; Wang Z
    Sci China Life Sci; 2020 Apr; 63(4):469-484. PubMed ID: 32086672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA therapeutics: RNAi and antisense mechanisms and clinical applications.
    Chery J
    Postdoc J; 2016 Jul; 4(7):35-50. PubMed ID: 27570789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing.
    Mourich DV; Iversen PL
    Curr Opin Mol Ther; 2009 Apr; 11(2):124-32. PubMed ID: 19330718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative Pre-mRNA Splicing, Cell Death, and Cancer.
    Ruirui K; Ray P; Yang M; Wen P; Zhu L; Liu J; Fushimi K; Kar A; Liu Y; He R; Kuo D; Wu JY
    Cancer Treat Res; 2013; 158():181-212. PubMed ID: 24222359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.